Cohance Lifesciences Ltd announced that the United States Food and Drug Administration (USFDA) has successfully completed a current Good Manufacturing Practices (cGMP) audit of its Active Pharmaceutical Ingredient (API) manufacturing facility (API Unit 1) at Jaggaiahpet, Andhra Pradesh.
The inspection, conducted from September 8 to September 11, 2025, concluded with zero Form 483 observations, indicating full compliance with USFDA standards.
The company stated that it remains committed to upholding the highest standards of quality and regulatory compliance across its operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets.